The US Patent Office has accepted patent application No 17/309,952, titled "An A3 adenosine receptor ligand for use for ...

An orally bioavailable small molecule drug, Namodenoson acts on the A3 adenosine receptor, which is over-expressed on the surface of liver pathological cells in MASH and not in normal cells.

Piclidenoson is a first-in-class, orally bioavailable anti-inflammatory drug with a proven safety record, targeting the A3 adenosine receptor. It has shown efficacy in earlier clinical trials and ...